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statistics for the goodness-of-fit. Differences between groups were analyzed by the χ 2 or Fisher's exact test. Two-tailed t-tests were performed to compare IHC scores between groups of patients.
Logistic regression models assessed associations between genotypes and clinicopathological features. Event-free survival (EFS) and overall survival (OS) encompassed time from diagnosis until relapse, progressive disease, death due to disease effects or last follow-up, and time from diagnosis until death by any cause or last follow-up, respectively, and were considered only in the 139 patients treated with CHOP or R-CHOP. EFS and OS probabilities were estimated by the Kaplan-Meier method, and curves were compared by the log-rank test. The Cox hazards model was used to identify variables predicting EFS and OS. Variables with P o 0.15 in univariate analyses were included in multivariate analysis. Significant results of Cox analyses were validated using a bootstrap resampling study to investigate the stability of risk estimates (1000 replications). Differences were significant when P o0.05.
Both patients (χ 2 = 0.0002, P = 0.98) and controls (χ 2 = 1.73, P = 0.18) satisfied the HWE at the VEGFA-2578 C4A locus. The mean age of patients was higher than that of controls (56 vs 50 years, Po0.001). Similar frequencies of VEGFA CC genotype were seen in patients and controls (39.2% vs 36.8%, P = 0.34), after adjustment by differences in age of groups, and individuals with the CC genotype were under similar risks of FL than the ones carrying CA or AA genotypes (odds ratio: (Figures 1a-c) .
At the study end (May 2016), 116 patients were alive and 23 patients had died. The median follow-up time was 41.0 months (1.7-196.1). The 60-month EFS and OS for all patients were 56.5% and 80.5%, respectively. At this time, both EFS and OS were shorter in patients with B symptoms (40.9% vs 67.9%, P o 0.01; 66.4% vs 90.1%, P o 0.01), FLIPI of high risk (33.2% vs 68.3%, P o0.01; 59.4% vs 91.0%, P o 0.01) and VEGFA CC genotype (42.4% vs 68.3%, P = 0.02; 65.3% vs 91.1%, P o 0.01), respectively (Figures 1d and e). Bulky disease predicted only worse OS (65.0% vs 87.7%, P = 0.03), and bone marrow infiltration was marginally associated with shorter EFS (37.0% vs 59.6%, P = 0.05). No differences in EFS or OS were seen in patients treated with CHOP or R-CHOP (Figures 1f and g ) (Kaplan-Meier estimates). In univariate Cox analysis, B symptoms, FLIPI score and VEGFA-2578 C4A predicted EFS and OS, and bulky disease influenced only OS. In multivariate analysis, B symptoms predicted EFS, bulky disease predicted OS and VEGFA-2578 C4A influenced both EFS and OS. Univariate and multivariate analyses showed that patients with the VEGFA CC genotype had a 1.84-and 1.82-fold higher risk of presenting an event and a 3.76-and 3.35-fold increased risk of progression to death than others, respectively. All associations seen in Cox analyses were validated by bootstrap studies based on 1000 samples (Table 1) .
We initially observed that the rs699947 SNP was unimportant in FL development, but had a relevant role in determining tumor burden, aggressiveness and vascularization at diagnosis. In fact, increased blood vessels may determine non-Hodgkin lymphoma progression, probably due to increased supplies of oxygen and nutrients to tumor cells. 2, 4 Second, we found lower EFS and OS in patients with B symptoms, bulky disease and FLIPI of high risk, as expected, and observed that patients with the VEGFA CC genotype presented poorer outcome than others. No association between rs699947 and patients' outcome was found in a large study in DLBCL and in a small MCL cohort. 11, 12 In contrast, a VEGFA haplotype, including the rs699947 locus, had deleterious effects in CLL patients. 13 Our results and those found in CLL support that AG modulation by rs699947 may be relevant driving indolent lymphoproliferative diseases to unfavorable outcomes.
The VEGFA CC genotype was previously associated with higher protein expression in the peripheral blood of 30 healthy individuals 7 and 52 ovarian cancer patients. 8 We found, however, similar VEGFA expressions in tumors derived from FL patients with distinct genotypes, suggesting that the SNP does not affect protein levels. Interestingly, the final AG product, that is, microvessel density, was increased in biopsies of patients carrying the CC genotype. It seems, thus, that the functional role of rs699947 also exists in FL, but is not dependent on local VEGFA production, as similarly reported in other AG studies for FL. 5, 14 It is possible, however, that rs699947 affects systemic VEGFA levels in FL patients, as described in the abovementioned immunoassay studies. 7, 8 Complementarily, the lack of LG modulation by VEGFA-2578 C4A in our study suggests an exclusive role of the CC genotype in AG, which could increase resistance to apoptosis and tumor cell migration, leading ultimately to disease progression, as previously modeled. 13 Another report, in contrast, observed that higher VEGFA levels in lymphoma samples were correlated with increased LG. 5 However, only 11 FL cases were analyzed by the authors, hampering a more direct comparison with our results. In addition, our findings do not support a tumor VEGFA modulation dependent on rs699947. Growing evidences, however, point toward regulation of LG by the VEGFC gene, which might guide future investigations. 15 In summary, we present the first evidence regarding VEGFA-2578 C4A SNP role in clinicopathological aspects and as an independent prognostic factor in FL. However, we are aware that larger cohorts of various parts of the world and studies of systemic VEGFA production in patients carrying the different genotypes of the SNP are needed to give support to the findings. The number of patients differed from the total treated with CHOP/R-CHOP included in analysis of survival (N = 139) because it was not possible to obtain the information of interest in some patients. Letter to the Editor
